Brixton Biosciences

Brixton Biosciences is pioneering a novel approach to pain management with its ReneuRx™ therapy, a nerve-selective treatment intended to deliver months of pain relief from one injection. The company, founded by clinicians and researchers from Massachusetts General Hospital and Harvard Medical School, initiated its first-in-human clinical trial in 2023 for knee pain. Brixton aims to address the massive unmet need in pain control, potentially reducing reliance on short-acting anesthetics and opioids, which carry significant risks of addiction and abuse. Its initial focus is the orthopedic pain market, with a long-term vision to treat a broader spectrum of pain conditions.

ReneuRx™ nerve-selective therapy platform designed for reversible, long-duration (3+ months) pain inhibition via a single injection.

Brixton competes in the non-opioid pain management space, which includes pharmaceutical companies developing novel analgesics (e.g., NaV1.7/1.8 inhibitors), medical device firms with nerve stimulation or ablation technologies, and companies offering long-acting local anesthetic formulations. Its key differentiator is the claimed duration of effect (months from one injection) compared to hours/days for most alternatives.